Today's Breast Cancer Survivors Are Tomorrow's Cardiac Sufferers: A Narrative Review Implementing Resveratrol Against Doxorubicin-Induced Cardiotoxicity | ||||
| Zagazig University Medical Journal | ||||
| Volume 31, Issue 7, July 2025, Page 2868-2883 PDF (1.41 MB) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/zumj.2025.361468.3846 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Rana M. Bendary   1; Omar Y. El-Azzazy2; Nabila Hefzi 3; Hanan M. Elnahas 4
| ||||
| 1Pharmacy Practice Department, Faculty of Pharmacy, Zagazig University,Egypt | ||||
| 2Pharmacy Practice Department, Faculty of Pharmacy, Zagazig University, Egypt | ||||
| 3Department of Clinical Oncology, Faculty of Medicine, Zagazig university, Egypt | ||||
| 4Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig university, Egypt | ||||
| Abstract | ||||
| Background: Breast cancer (BC) is the most frequently diagnosed malignancy and a leading cause of mortality among females worldwide. Despite the prodigious advances of chemotherapeutic agents advocated for BC, however, a substantial coincident complication, particularly cardiotoxicity, is inevitably encountered and appears as devastating as cancer itself. It remains a conundrum that has not yet been solved. On this ground, “today's breast cancer survivors might be tomorrow's cardiac sufferers”. In this narrative review, we are spotting light on Doxorubicin (DOX)-induced cardiotoxicity and cropping up a snapshot on the polyphenolic Resveratrol supplement as a promising prophylactic approach. DOX is highly effective in managing BC by virtue of its cytotoxic, oxidant, proinflammatory, and proapoptotic effects. However, its clinical applicability has been curbed by its associated dose-dependent cardiotoxicity. This complication is a pressing argument and a highly challenging issue to be tackled. Nowadays, natural polyphenolic compounds conquer the field of cardio-oncology for the sake of their profound health benefits. Resveratrol, one of the most prevailing polyphenols, is merited to be discussed since it was renowned for its antioxidant, anti-inflammatory, and anti-apoptotic properties. These attributes have conferred it a promising cardioprotective effect that overlooked to date in various in vivo, in vitro, and clinical trial studies. Conclusion: Early detection and monitoring of DOX-induced cardiotoxicity is of great worth and incorporating Resveratrol supplement as a cardioprotective DOX adjuvant must gain much concern as a novel insight and a hopeful avenue to mitigate bad sequel of cardiotoxicity in DOX-treated BC patients and even survivors. | ||||
| Keywords | ||||
| Breast cancer; Doxorubicin; Cardiotoxicity; Resveratrol; Mitochondrial biogenesis | ||||
|
Statistics Article View: 8,229 PDF Download: 50 |
||||
